Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PD-L1.t-haNK cells |
| Synonyms | |
| Therapy Description |
PD-L1.t-haNK cells are natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) that targets PD-L1, which may induce cell killing in PD-L1-expressing tumor cells resulting in decreased tumor growth (PMID: 32439799). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PD-L1.t-haNK cells | PD-L1 t-haNK|Allogeneic PD-L1-t-haNK | PD-L1.t-haNK cells are natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) that targets PD-L1, which may induce cell killing in PD-L1-expressing tumor cells resulting in decreased tumor growth (PMID: 32439799). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04050709 | Phase I | PD-L1.t-haNK cells | QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers | Active, not recruiting | USA | 0 |